Gilead Sciences Inc (GILD) Common Stock USD0.001

- Add to watchlist
- This stock can be held in a




Share news, reports & tips
-
Gilead raises 2020 forecasts after Covid-19 surge boosts remdesivir
11 January 2021 13:46
(Sharecast News) - Gilead Sciences has upped its full-year profit guidance following strong sales of its Covid-19 treatment remdesivir.
-
FDA grants EUA for Eli Lilly treatment in conjunction with Remdesivir
20 November 2020 14:26
(Sharecast News) - The Food and Drug Administration has granted Emergency Use Approval for baricitinib, a treatment for Covid-19 developed jointly by Eli Lilly and Incyte, in combination with Gilead...
-
WHO advises against prescribing remdesivir for Covid-19
20 November 2020 12:35
(Sharecast News) - WHO advises doctors against treating Covid-19 patients with Gilead Science's remdesivir drug (under the name Veklury) that has "no meaningful effect" on survival or need for...
-
Eli Lilly halts late stage trial into Covid-19 antibody treatment, but 'confident' it works
27 October 2020 14:28
(Sharecast News) - Eli Lilly and researchers at the National Institutes of Health have paused a late-stage clinical trial into a combination of the company's antibody treatment against Covid-19 in...
-
FDA grants full approval to Gilead Sciences's Veklury for Covid-19
23 October 2020 11:28
(Sharecast News) - Gilead Sciences's antiviral Veklury, better known as Remdesivir, was given the stamp of the approval by the country's health watchdog overnight for use as a treatment against...
-
Gilead Sciences's Remdesivir may cut Covid-19 risk of death by 62%
10 July 2020 14:09
(Sharecast News) - Gilead Sciences's Remdesivir antiviral treatment for the novel coronavirus may cut the risk of death by nearly two-thirds.
-
Gilead Sciences to test inhaled version of Covid-19 treatment, Remdesivir
22 June 2020 18:32
(Sharecast News) - US biotechnology giant Gilead Sciences will start testing an inhaled version of its treatment for Covid-19, Remdesivir, in August.
-
JP Morgan stays at overweight on AstraZeneca following merger rumours
8 June 2020 14:43
(Sharecast News) - JP Morgan has reiterated its 'overweight' rating on AstraZeneca, following reports that the drugs manufacturer was mulling a possible merger with US rival Gilead Sciences.
-
AstraZeneca approached Gilead about merger - report
8 June 2020 07:33
(Sharecast News) - AstraZeneca has approached Gilead Sciences of the US about a potential merger to create a $240bn drugmaker, according to a report.
-
Sunday newspaper round-up: Pandemic, Jobs, AstraZeneca
7 June 2020 12:21
(Sharecast News) - Fresh evidence of China's shocking cover-up of the pandemic outbreak has been found in censored media reports from Wuhan. Samples taken from sick patients and analysed by at least...
-
Japan approves Gilead Sciences's Remdesivir for use in expedited process
7 May 2020 15:34
(Sharecast News) - Japanese health authorities have approved Gilead Sciences's Remdesivir anti-viral drug as a treatment for Covid-19.
-
Gilead Sciences shares halted after 'positive data' from clinical trial
29 April 2020 13:53
(Sharecast News) - Shares of US biotechnology outfit Gilead Sciences were halted after the company notified markets that "positive data" were emerging from a clinical trial being conducted by the...
Company announcements Announcements
No company announcements about Gilead Sciences Inc Common Stock USD0.001 were found.
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2022. All rights reserved.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.